Connect with us

Technology

Clairity Appoints Jeffrey R. Luber CEO as Firm Prepares for Global Expansion

Published

on

Company Poised to Revolutionize Breast Cancer Screening through AI-based Risk Prediction

BOSTON, Nov. 5, 2024 /PRNewswire/ — Clairity, Inc., a pioneer in AI-based predictive tools for breast cancer, is pleased to announce the appointment of Jeffrey R. Luber, JD, MBA, as President, Chief Executive Officer and Director. Luber, an award-winning healthcare leader with extensive experience across oncology, genetic sequencing, infectious disease testing and digital health, will guide Clairity through market launch and global expansion. Clairity’s AI-driven offering is poised to introduce image-based breast cancer risk prediction on a global scale.

“I’m excited to join Clairity at this pivotal moment,” said Luber. “Too many patients receive a cancer diagnosis when it’s too late to make a real difference. Clairity is focused on development of products that shift the current screening paradigm for patients – identifying high risk patients earlier to impact patient care and prognosis. By delivering personalized, AI-powered risk assessments, Clairity’s platform will empower clinicians and patients to take clinically-sound, data-driven action sooner than what has previously been possible with mammography alone.”

Clairity’s mission is to improve breast cancer screening for everyone, regardless of race, ethnicity, or geography. Allix5, the company’s first product, uses AI-derived analysis of a screening mammogram designed to identify patients at increased risk of developing breast cancer. The platform draws on vast and diverse imaging data and clinical outcomes from around the world that the company believes will offer novel opportunities for risk prediction. 

Dr. Connie Lehman, MD, PhD, co-founder of Clairity and a leading authority in breast imaging AI, emphasized the transformative role of machine learning and AI in enhancing mammography workflows. “Our research and collaborations have paved the way for a new era in breast cancer screening,” said Dr. Lehman. “Jeff’s leadership across some of the most innovative life sciences companies is invaluable as we navigate this next chapter of exciting growth for Clairity. I am excited to partner with Jeff, the Clairity team, and the clinical community in deploying AI prognostics for millions of women at risk.”

“With the planned global launch, Luber’s appointment underscores Clairity’s and Santé’s commitment to revolutionizing breast cancer care,” said Kevin Lalande, Founding Managing Director of Santé, an early-stage healthcare and life sciences investment firm who is a lead investor in Clairity. “Since its inception, I’ve been impressed by Clairity’s unwavering commitment to clinical and scientific rigor, its focus on patient diversity in the development of its algorithms, and the vast opportunity before us to reduce global breast cancer mortality through the power of AI. Jeff’s addition to the team positions us exceptionally well for commercial growth and achievement of our mission in women’s health.”

Luber’s extensive career includes leading multiple healthcare companies through the complete arc of maturation from research entities, through pre-clinical work, FDA submission and clearance, market launch, commercial growth, and company exit. Regarded as a builder of enduring relationships and value-enhancing partnerships, Luber served most recently as CEO of binx health, where he led the company to first-in-market status in a $2B category for infectious disease point-of-care testing and also founded the firm’s at-home digital health arm, reaching millions in underserved areas and generating tens of millions in revenue. Luber continues to serve as binx Chairman today.

His previous roles also include CEO of Good Start Genetics (sold to Invitae in 2017) and President & CEO of Exact Sciences, where he helped establish DNA-based testing for colorectal cancer as a new standard for millions, winning endorsement from the American Cancer Society and World Gastroenterology Organization under his leadership.

About Clairity, Inc.
Clairity, Inc. is at the forefront of leveraging AI to improve breast cancer screening and risk assessment. Through advanced imaging data and predictive algorithms, Clairity’s platform is designed to provide clinicians and patients with personalized, actionable information. Clairity is dedicated to making precision medicine a reality for everyone.

About Santé Ventures
Founded in 2006, Santé Ventures is a specialized healthcare and life sciences investment firm with roughly $800 million in capital under management. The firm invests in early-stage companies developing innovative new medical technologies, biotechnologies, and digitally enabled healthcare services. Recent Santé successes include Laminar (Johnson & Johnson), Farapulse (Boston Scientific), Claret Medical (Boston Scientific), TVA Medical (Becton Dickinson), Millipede Medical (Boston Scientific), Molecular Templates (MTEM), AbVitro (Bristol Myers Squibb), and Explorys (IBM Corp). Santé invests nationally and has offices in Austin, TX, and Boston, MA. For more information, please visit www.sante.com.

Media Contacts
Ryan Walker
R.J. Walker & Co.
ryan@rjwalkerco.com
860.930.3611

View original content:https://www.prnewswire.com/news-releases/clairity-appoints-jeffrey-r-luber-ceo-as-firm-prepares-for-global-expansion-302295930.html

SOURCE Clairity, Inc.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Duoning Biotech announced strategic partnership with Branca Bunús to promote the next generation of transfection reagents

Published

on

By

SHANGHAI, Nov. 5, 2024 /PRNewswire/ — Duoning Biotechnology Group (“Duoning”) announced a strategic partnership agreement with Branca Bunús Ltd. (“Branca Bunús”). Under this agreement, the two companies will collaborate on the development, optimization, and application of transfection reagents, with the goal of providing  biopharmaceutical customers with innovative transfection reagents through resource sharing, thereby enhancing the efficiency of biopharmaceutical development in upstream bioprocess.

Branca Bunús is a gene delivery technology company based in Ireland, specializing in the development of safe gene delivery vectors and effective transfection reagents derived from unique cationic polymer materials. Guided by a product development philosophy that emphasizes high efficiency, biocompatibility, and significant clinical and industrial application value, Branca Bunús has created the BrPERfect® series of transfection reagents. The company also offers supporting services, including the development of targeted gene delivery vectors and directional optimization. As a well-established one-stop bioprocess solution provider in China, Duoning Biotech’s offerings encompass the entire bioprocess workflow, from upstream cell culture to downstream filtration and purification. Additionally, Duoning Biotech provides services such as media production, process optimization, and validation testing.

After the cooperation is established, Branca Bunús will be responsible for the research, development, and performance enhancement of transfection reagents. This includes scientific research applications involving DNA, siRNA, and mRNA transfection, as well as the production of recombinant proteins, AAV, and LV based on the transient transfection of CHO and HEK 293 cells. Duoning will leverage its established sales network and collaborative sales strategy for upstream process products to comprehensively promote this solution. Additionally, both parties will form a specialized research and marketing team to optimize the transient transfection process by examining the interaction principles of transfection reagents and cell culture media. They will also conduct market research to develop a comprehensive solution for the application of transfection reagents.

Hongfeng Gu, Vice President of Duoning, stated, “Branca Bunús is an emerging biotechnology company that has developed a leading hyperbranched polymer gene delivery vector platform, founded by Professor Wenxin Wang. We are honored to collaborate with companies that possess core technologies. The BrPERfect® series of transfection reagents from Branca Bunús, combined with Duoning’s cell culture media, bioreactors, and other products, will offer customers more comprehensive upstream bioprocessing solutions.”

Dr. Zhonglei He, Chief Technology Officer of Branca Bunús, stated, “The significant contribution of Duoning to the rapid development of the biotechnology market is evident to all. We are honored to collaborate with Duoning, particularly in its one-stop bioprocessing solutions. Our goal is to provide efficient and stable transfection reagent products and process support, ensuring timely and high-quality products and services for various R&D and production applications, including transient protein production and screening in downstream processes, stem cell enhancement, and the production of diverse viral vectors through transient transfection.”

About Duoning

Shanghai Duoning Biotechnology Co., Ltd. (“Duoning”) is a leading one-stop bioprocess solutions provider in China, committed to offering products and services required for the discovery, development and commercialization production of biologics, including reagents, consumables, instruments, equipment, and validation services. Leveraging our integrated bioprocess system, we empower our partners to achieve effective, reliable, lower-cost and higher-quality biologics production processes. For more information, please visit: www.duoningbio.com/en

For media inquiries, please contact: PR@duoningbio.com 

About Branca Bunús

Branca Bunús is an emerging Irish biotechnology company specializing in innovative gene delivery technologies. Leveraging over a decade of research by its founding technical team, the company focuses on the development and production of advanced gene delivery vectors and transfection reagents. Branca Bunús aims to provide cost-effective, high-yield transient transfection solutions, along with supporting services such as targeted gene delivery vector development and directional optimization. The company is dedicated to transforming groundbreaking discoveries into life-changing practical applications. To learn more, please visit: http://brancabunus.com

View original content:https://www.prnewswire.com/news-releases/duoning-biotech-announced-strategic-partnership-with-branca-bunus-to-promote-the-next-generation-of-transfection-reagents-302297073.html

SOURCE Duoning

Continue Reading

Technology

UnionPay International joins forces with industry players to optimize payment experience for international visitors to China

Published

on

By

Global UnionPay Cards Now Support Weixin Pay and Alipay

SHANGHAI, Nov. 5, 2024 /CNW/ — UnionPay International (UPI) announced that Alipay and Weixin payments are fully enabled for UnionPay cards issued outside China’s mainland, providing more diversified, convenient and inclusive payment options for inbound travelers to China. The collaboration with Weixin Pay is supported through the Industrial and Commercial Bank of China (ICBC).

In order to further optimize payment services, UnionPay launched Project Excellence 2024 in March, joining hands with various industry stakeholders to build a convenient, inclusive, and accessible payment ecosystem. This collaboration is the latest achievement of the Project. From now on, international travelers to China can download Alipay or Wexin applications, link their local UnionPay cards, and enjoy the same convenience of QR payments as the Chinese users do.

This innovative payment method will provide more convenience for inbound visitors to pay in China: No service fee will apply throughout the payment process as initial promotion, which enables users to make payments as if they were at home. Online and offline use cases are covered, including F&B, accommodation, transit, sightseeing, shopping and entertainment. The new method supports consumer-presented, merchant-presented, in-app payment and ETC, which removes the payment barriers for users who are travelling, working or living in China. The new enablement is easy to use, as cardholders only need to enter the UnionPay card information required, and complete the linking process once the card issuer performs the authentication.

This collaboration manifests UPI’s stepped-up efforts to work with other industry stakeholders to promote payment interoperability and develop a sustainable business model. It will help to further bridge the differences in payment preference between China and the rest of the world, facilitate the country’s high-standard opening up.

UnionPay’s international business has become increasingly localized in the past few years, and more and more consumers outside China are enjoying the convenient services brought by UnionPay. Over 250 million UnionPay cards have been issued in 83 countries and regions outside China’s mainland, which can be used for payments in 183 countries and regions. UnionPay has also launched SplendorPlus, a new card product tailored to international visitors to China. The themed card, which comes with diverse benefits and special merchant offers in China, has proven to be highly popular.

 

View original content:https://www.prnewswire.com/news-releases/unionpay-international-joins-forces-with-industry-players-to-optimize-payment-experience-for-international-visitors-to-china-302296568.html

SOURCE UnionPay International

Continue Reading

Technology

Horizons Shines at CIIE 2024 with Global Leader Recognition in G2’s Fall 2024 Reports

Published

on

By

SHANGHAI, Nov. 5, 2024 /PRNewswire/ — Horizons, a leading global Employer of Record (EOR) provider, proudly launches its latest Global HR Strategy at the 2024 China International Import Expo (CIIE) from November 5 to 10 in Shanghai. Under the theme “Talent Without Borders, Vision Without Limits,” Horizons will showcase its commitment to empowering a borderless workforce and present its innovative SaaS HR platform, designed to enhance HR compliance, simplify payroll, and streamline employee and contractor payment for businesses worldwide..

At CIIE, Horizons will demonstrate how advancements in technology, including AI, big data, and cloud computing, are reshaping HR management. The event will also highlight Horizons’ strategic collaborations with other innovators in the sector to support both global and Chinese enterprises in expanding their workforces across borders.

Coinciding with its presence at CIIE, Horizons has been recognized as a Global Leader in G2‘s Fall 2024 Reports across multiple categories in Global Employment Platforms (GEP) and Contractor Management. This recognition underscores Horizons’ dedication to a full range of global hiring solutions, covering both contractors and employees.

Horizons Fall 2024 G2 Recognitions

Leader in Mid-Market EMEA Contractor ManagementLeader in EMEA Global Employment Platforms (GEP)Leader in Mid-Market Global Employment Platforms (GEP) – Recognized for Easiest Admin and Easiest To Do Business WithLeader in Global Employment Platforms (GEP) – Recognized for Easiest AdminLeader in Small-Business Global Employment Platforms (GEP)Users Love Us: Awarded for consistently high customer satisfaction ratings

“Horizons’ mission is to build solutions that empower the borderless workforce, and our vision is to create equal opportunity for all,” said Antoine Boquen, Horizons’ CEO and Co-founder. “Our G2 recognition across multiple categories, and presence at CIIE, reflect our continued dedication to businesses of all sizes in their global hiring journey.  We firmly believe that location should be no barrier to businesses hiring the best talent, and professionals finding the best workplace.

About Horizons

Horizons is a leading global Employer of Record (EOR), transforming how businesses hire internationally. Our innovative platform simplifies global hiring by managing compliance, payroll, and payments through established local infrastructure in over 100 countries. Trusted by over 3,000 businesses, Horizons enables companies of all sizes to hire overseas talent quickly and cost-effectively.

Learn more: https://joinhorizons.com/

Contacts

Lily Zhang, Digital Marketing Manager at Horizons

lily.zhang@horizons.com 

View original content:https://www.prnewswire.com/news-releases/horizons-shines-at-ciie-2024-with-global-leader-recognition-in-g2s-fall-2024-reports-302296380.html

SOURCE Horizons

Continue Reading

Trending